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Breast cancer (Bc) is the leading cause of cancer-related death among women and the most commonly 
diagnosed cancer worldwide. Although in recent years large-scale efforts have focused on identifying 
new therapeutic targets, a better understanding of BC molecular processes is required. Here we focused 
on elucidating the molecular hallmarks of BC heterogeneity and the oncogenic mutations involved in 
precision medicine that remains poorly defined. To fill this gap, we established an OncoOmics strategy 
that consists of analyzing genomic alterations, signaling pathways, protein-protein interactome 
network, protein expression, dependency maps in cell lines and patient-derived xenografts in 230 
previously prioritized genes to reveal essential genes in breast cancer. As results, the OncoOmics BC 
essential genes were rationally filtered to 140. mRNA up-regulation was the most prevalent genomic 
alteration. The most altered signaling pathways were associated with basal-like and Her2-enriched 
molecular subtypes. RAC1, AKT1, CCND1, PIK3CA, ERBB2, CDH1, MAPK14, TP53, MAPK1, SRC, RAC3, 
BCL2, CTNNB1, EGFR, CDK2, GRB2, MED1 and GATA3 were essential genes in at least three oncoomics 
approaches. Drugs with the highest amount of clinical trials in phases 3 and 4 were paclitaxel, 
docetaxel, trastuzumab, tamoxifen and doxorubicin. Lastly, we collected ~3,500 somatic and germline 
oncogenic variants associated with 50 essential genes, which in turn had therapeutic connectivity with 
73 drugs. In conclusion, the OncoOmics strategy reveals essential genes capable of accelerating the 
development of targeted therapies for precision oncology.
Breast cancer (BC) is a complex and heterogeneous disease characterized by an intricate interplay between dif-
ferent biological aspects such as ethnicity, genomic alterations, gene expression deregulation, hormone disrup-
tion, signaling pathway alterations, hypoxia, and environmental determinants1,2. Over the last years, prevention, 
treatment and survival strategies have evolved favorably; however, there are BC profiles that remain incurable3. 
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Nowadays, BC is the leading cause of cancer-related death among women (627,000; 15% cases) and the most 
commonly diagnosed cancer (2,088,849; 24% cases) worldwide4.
The development of large-scale DNA sequencing, gene expression, proteomics, large-scale RNA interference 
(RNAi) screens, large-scale CRISPR-Cas9 screens and patient-derived xenografts (PDXs) has allowed us to better 
understand the molecular landscape of oncogenesis. Considerable progress has been made in discovering coding 
and non-coding somatic drivers5,6, cancer driver genes7,8, cancer driver mutations9,10, germline variants11, driver 
fusion genes12,13, alternatively spliced transcripts14, expression-based stratification15, molecular subtyping16, bio-
markers17, druggable enzymes18, cancer dependencies19–22, and drug resistance23.
Scientific advances made to date mark the era called the “end of the beginning” of cancer omics. In other 
words, each approach that was previously mentioned needs to be fully understood as a part of a complex network, 
analyzing the mechanistic interplay of signaling pathways, protein-protein interactome (PPi) networks, enrich-
ment maps, gene ontology (GO), deep learning, molecular dependencies and genomic alterations per intrinsic 
molecular subtype: basal-like (estrogen receptor (ER)−, progesterone receptor (PR)−, human epidermal growth 
factor receptor 2 (Her2)−, cytokeratin 5/6+ and/or EGFR+); Her2-enriched (ER−, PR−, Her2+); luminal A (ER+ 
and/or PR+, Her2−, low Ki67); luminal B with Her2− (ER+ and/or PR+, Her2−, low Ki67); luminal B with Her2+ 
(ER+ and/or PR+, Her2+, any Ki67); and normal like24–30.
Here we focus on elucidating the molecular hallmarks of BC essential genes and the oncogenic mutations 
applied in precision medicine that remains poorly defined. To fill this gap, we propose the OncoOmics strat-
egy that consists in the analysis of genomic alterations (mRNA up-regulation, mRNA down-regulation, putative 
driver mutation, copy number variant (CNV) amplification, CNV deep deletion, and fusion gene), signaling 
pathways, PPi network, protein expression, BC dependencies in cell lines and patient-derived xenografts in a set 
of previously prioritized genes. These genes will come from our Consensus Strategy (CS) study29, the Pan-Cancer 
Atlas (PCA) project3,13,31–37, the Cancer Genome Interpreter (CGI) study38, and the Pharmacogenomics 
Knowledgebase (PharmGKB)39.
In our previous studies, López-Cortés et al., Tejera et al., and Cabrera-Andrade et al., developed a Consensus 
Strategy that was proved to be highly efficient in the recognition of gene-disease association29,40,41. The main 
objective was to apply several bioinformatics methods to explore BC pathogenic genes. On the other hand, The 
Cancer Genome Atlas (TCGA) has concluded the most sweeping cross-cancer analysis yet undertaken, namely 
the PCA project32. PCA reveals how genomic alterations and protein expression collaborate in BC progression, 
providing insights to prioritize the development of new treatments3,13,31–37. The CGI flags genomic biomarkers 
of drug response with different levels of clinical relevance38. Lastly, PharmGKB is a comprehensive resource that 
curates and spreads knowledge of the impact of clinical annotations on drug response39,42. PharmGKB collects the 
precise guidelines for the application of precision medicine and pharmacogenomics in clinical practice published 
by the European Society for Medical Oncology (ESMO), the National Comprehensive Cancer Network (NCCN), 
the Royal Dutch Association for the Advancement of Pharmacy (DPWG), the Canadian Pharmacogenomics 
Network for Drug Safety (CPNDS) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)43–46. 
Hence, we identified essential genes, oncogenic mutations and potential therapeutic targets that could be incor-
porated into strategies aimed at improving novel drug development and precision medicine in BC.
Results
OncoPrint of genomic alterations according to the Pan-Cancer Atlas. PCA has reported the clin-
ical data of 1084 individuals with BC and it can be visualized in the Genomic Data Commons of the National 
Cancer Institute and in the cBioPortal47,48. In regard to molecular subtypes and tumor stages, 46% were lumina 
A, 18% luminal B, 7% Her2-enriched, 16% basal-like and 3% normal-like, whereas 17% were tumor stage 1 (T1), 
58% T2 stage, 23% T3 stage and 2% T4 stage (Supplementary Table S1).
Figure 1a shows the frequency mean of genomic alterations per gene set. The frequency mean of the PCA 
gene set was 1.3, followed by the CS gene set (1.2), the PharmGKB/CGI gene set (1.0), BC driver genes (0.8), 
and non-cancer genes (0.4) (Supplementary Table S2). Consequently, we performed a multiple comparison of 
the genomic alteration frequencies using the Bonferroni correction in order to determine statistical significance 
among gene sets. There were significant differences between BC driver genes and non-cancer genes (P < 0.001), 
the PCA gene set and BC driver genes (P < 0.001), and the CS gene set and BC driver genes (P < 0.001). Hence, 
the fact that gene sets of interest (CS and PCA) presented significant differences in the amount of genomic alter-
ations versus BC driver genes could indicate that we are analyzing potentially essential genes in BC. Figure 1b 
shows the percentage of genomic alterations per type. The most common genomic alterations were mRNA 
up-regulation (55.8%), CNV amplification (17.1%), and missense mutations (8.4%). Figure 1c shows the ratio of 
genomic alterations in the 230 genes per sample and molecular subtype. Basal-like had the highest ratio (n = 33), 
followed by Her2-enriched (29), luminal B (24), normal-like (17), and luminal A (15). The ratio of all BC samples 
was 19.6. Figure 1d shows the ratio of genomic alterations in the 230 genes per sample and tumor stage. T2 stage 
had the highest ratio (23), followed by T3 (22), T1 (17) and T4 (8). Figure 1e,f show the percentage of genomic 
alterations per subtype and tumor stage, respectively. mRNA up-regulation and CNV amplification were the most 
common alterations in all molecular subtypes and tumor stages.
Figure 2 shows the ranking of genes with the highest amount of genomic alterations per molecular subtype 
and tumor stage. Regarding molecular subtypes, PIK3CA was the most altered gene in luminal A, CCND1 in 
luminal B, TP53 in basal-like and normal-like, and ERBB2 in Her2-enriched (Fig. 2a). Figure 2b–f show genes 
with the highest ratio of mutations, CNV amplifications, CNV deep deletions, mRNA up-regula tions, and mRNA 
down-regulations per molecular subtype (Tables S3–S7). After Bonferroni  correction, we obtained statistically 
significant differences (P < 0.05) regarding CNV amplifications, CNV deep deletions, mRNA up-regulations, 
and mRNA down-regulations among molecular subtypes. On the other hand, the most altered genes per tumor 
stage were PIK3CA in T1 stage, TP53 in T2 and T3, and ERBB2 in T4 (Fig. 2g). Figure 2h–l show genes with the 
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highest percentage of mutations, CNV amplifications, CNV deep deletions, mRNA up-regulations, and mRNA 
down-regulations per tumor stage (Tables S8–S12). We found statistically significant differences (P < 0.05) 
regarding all genomic alterations among tumor stages using the Bonferroni correction test.
The first OncoOmics approach was focused on genes with the highest amount of genomic alterations (more 
than the average). The panoramic landscape of genomic alterations was termed OncoPrint and is shown in Fig. 3a. 
Putative driver mutations were taken into account for this analysis, discarding passenger mutations (Figure S1 
and Supplementary Table S13). Figure 3b,c show circos plots of interactions among molecular subtypes, tumor 
stages, and genomic alterations of the most altered genes (Supplementary Table S14). Highest amount of fusion 
genes were in Her2-enriched subtype and T4 stage, highest amount of mRNA down-regulation + CNV deep 
deletion were in basal-like subtype and T4 stage, highest amount of mRNA up-regulation + CNV amplification 
were in basal-like subtype and T4 stage, lastly, highest amount of putative driver mutations were in Her2-enriched 
subtype and T3 stage. As result, the first OncoOmics approach reveled 73 essential genes with highest frequencies 
of genomic alterations.
Figure 1. Genomic alterations of the breast cancer cohort according to PCA. (a) Frequency of genomic 
alterations per gene set (non-cancer genes, BC driver genes according to the Network of Cancer Genes, 
Consensus Strategy, BC genes according to PCA, BC biomarkers according to the PharmGKB and CGI). 
Bonferroni correction with significant level of P < 0.05 and a 95% confidence interval was performed. (b) 
Percentage of genomic alterations per type. (c) Ratio of genomic alterations per intrinsic molecular subtype. 
(d) Ratio of genomic alterations per tumor stage. (e) Percentage of genomic alterations per type and molecular 
subtype. (f) Percentage of genomic alterations per type and tumor stage.
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* Ratio of genomic alterations per sample and per intrinsic molecular subtype
           Bonferroni correction
           p > 0.05 among all subtypes
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Figure 2. Ranking of genes with the highest amount of genomic alterations per molecular subtype and tumor 
stage. (a) Frequency of genomic alterations (punctual mutations, copy number variants and mRNA expression) 
per molecular subtype. (b) Frequency of genomic alterations per tumor stage. (c) Frequency of punctual 
mutations per molecular subtype. (d) Frequency of punctual mutations per tumor stage. (e) Frequency of CNV 
amplifications per molecular subtype. (f) Frequency of CNV amplifications per tumor stage. (g) Frequency 
of CNV deep deletions per molecular subtype. (h) Frequency of CNV deep deletions per tumor stage. (i) 
Frequency of mRNA up-regulation per molecular subtype. (j) Frequency of mRNA up-regulation per tumor 
stage. (k) Frequency of mRNA down-regulation per molecular subtype. (L) Frequency of mRNA down-
regulation per tumor stage.
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Pathway enrichment analysis. This enrichment analysis was performed using David Bioinformatics 
Resource to obtain integrated information from the Kyoto Encyclopedia of Genes and Genomes (KEGG)49–52. 
The enrichment analysis of signaling pathways was carried on in the 230 genes, obtaining more than 50 terms 
with a Benjamini-Hochberg - false discovery rate (FDR) <0.01 (Supplementary Table S15). Subsequently, 
genomic alterations of genes that make up each signaling pathway were analyzed according to the molecular 
















































































































































Figure 3. OncoPrint of genomic alterations according to the Pan-Cancer Atlas. (a) OncoPrint of genes with 
more genomic alterations than the average (>86) per molecular subtype. (b) Circos plot between molecular 
subtypes and the highest amount of genomic alterations (fusion genes, mRNA down-regulation plus CNV deep 
deletion, mRNA upregulation plus CNV amplification, and driver mutations). (c) Circos plot between tumor 
stages and the highest amount of genomic alterations.
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(Supplementary Table S16). NF-kappa ß, NOD-like receptor, adipocytokine, GnRH, RIG-like receptor, TNF, 
TGFß, FOXO, glucagon, MAPK, prolactin, cAMP, PI3K-AKT, neurotrophin, VEGF, notch, p53, sphingolipid 
and Wnt signaling pathways were more altered in basal-like; estrogen, HIF1, toll-like receptor, ras, insulin, T-cell 
receptor, rap1, ERBB, AMPK, chemokine, B-cell receptor, mTOR, Fc-epsilon RI, Jak-STAT, phosphatidylinositol 
and thyroid hormone pathways were more altered in Her2-enriched; and Hippo pathway in normal-like. On the 
other hand, Fig. 4b shows the ranking of the most altered signaling pathways per molecular subtype. Jak-STAT 
pathway was more altered in luminal A; Wnt pathway in luminal B; p53 pathway in basal-like; ERBB pathway in 
Her2-enriched; and Hippo pathway in normal-like (Supplementary Table S17). After Bonferroni correction, we 
observed statistically significant differences (P < 0.001) regarding the amount of genomic alterations in signaling 
pathways among molecular subtypes.
Figure 4c shows a circos plot correlating tumor stages with signaling pathways according to the frequency of 
genomic alterations (Supplementary Table S16). NOD-like receptor, adipocytokine, GnRH, TNF, estrogen, pro-
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Figure 4. Pathway enrichment analysis per molecular subtype and tumor stage. (a) Circos plot between 
molecular subtypes and the most altered signaling pathways. (b) Violin plots showing the frequency of the most 
altered signaling pathways per molecular subtype. (c) Circos plot between tumor stages and the most altered 
signaling pathways. (d) Violin plots showing the frequency of the most altered signaling pathways per tumor 
stage.
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epsilon RI, NOTCH, p53, sphingolipid and Wnt pathways were more altered in stage T2; NF-kappa ß, Hippo and 
phosphatidylinositol pathways were more altered in T3 stage; and RIG-like receptor, HIF1, TGFß, toll-like recep-
tor, insulin, AMPK, ERBB, chemokine, neurotrophin, mTOR, jak-STAT and thyroid hormone pathways were 
more altered in T4 stage. On the other hand, Fig. 4d shows the ranking of the most altered signaling pathways per 
tumor stage. Wnt pathway was more altered in T1, T2 and T3 stages; and thyroid hormone pathway was more 
altered in T4 stage (Supplementary Table S18). We found statistically significant differences (P < 0.001) regarding 
the amount of genomic alterations in signaling pathways among different tumor stages using the Bonferroni 
correction test.
Protein-protein interactome network. The second OncoOmics approach was focused on proteins with 
the highest degree centrality and consensus score in the String PPi network. The PPi network was performed to 
better understand BC behavior using the String Database and Cytoscape53,54. With the indicated cutoff of 0.9, the 
final interactome network had 258 nodes conformed by 198 (86%) proteins from the CS, PCA and PharmGKB/
CGI sets. Regarding nodes with the highest amount of genomic alterations showed previously in the OncoPrint, 
65 (89%) of them integrated this network (Fig. 5a). On the other hand, out of the 258 proteins that make up our 
String PPi network, 16 (6%) proteins and 18 edges were part of the OncoPPi BC network55,56. The degree central-
ity made it possible to establish a significant correlation (Spearman test, P < 0.05) between our String PPi network 
and the OncoPPi BC network (Fig. 5b).
Considering degree centrality and consensus scores from our previous study29, there was enrichment among 
sub-networks (Fig. 5a,b). The degree centrality average in the whole network was 48.8, and out of the OncoPPi 
BC network was 124.4. Meanwhile, the average of consensus score of the whole network was 0.803, and out of the 
OncoPPi BC network was 0.885. As result, the second OncoOmics approach reveled 40 proteins with both the 
highest degree centrality and consensus score, as shown in Supplementary Table S19.
Protein expression analysis. The third OncoOmics approach was focused on proteins with considera-
ble high and low expressions in BC. Figure 6a shows 43 proteins with significant high expression (Z-scores ≥ 
2) and low expression (Z-scores ≤ −2) analyzed with the reverse-phase protein array (RPPA) and mass spec-
trometry, in a cohort of 994 individuals according to TCGA (Supplementary Table S20). On the other hand, the 
Human Protein Atlas (HPA) presented a map of the human tissue proteome based on tissue microarray-based 
immunohistochemistry. HPA has analyzed 202 (88%) of the 230 proteins of our study, classifying the protein 
expression in high, medium, low and non-detected. As results, RAC1, GJB2, MED1, PIK3CA, PIK3R3, FGFR2, 
HCFC2, MAP2K4, NQO2 and RAC3 were proteins with high/medium expression in normal tissue, and low/
non-detected expression in BC tissue. Meanwhile, CDK2, CYP2D6, NCOR1, RRM1, FOXA1 and TOP2A were 
proteins with hi gh/medium expression in BC tissue, and low/non-detected expression in normal tissue (F ig. 6b 
and Supplementary Table S21)57,58. As result, the third OncoOmics approach revealed 60 proteins with significant 
altered expression levels as shown in Tables S20 and S21.
Breast cancer dependency map. The first analysis of the fourth OncoOmics approach consisted in 
identifying genes that are essential for breast cancer cell proliferation and survival performing systematic 
loss-of-function screens in a large number of well-annotated cell lines representing the tumor heterogeneity19–22. 
Figure 7a shows the distribution of dependency scores of 227 genes through DEMETER2, an analytical frame-
work for analyzing genome-scale RNAi loss-of-function screens in 73 BC cell lines (Supplementary Table S22). 
Our results showed 563 dependencies with at least one score ≤ −1 in 57 (25%) essential genes. At the same time, 
Fig. 7a shows the distribution of dependency scores of 217 genes through CERES, an analytical framework for 
analyzing genome-scale CRISPR-Cas9 loss-of-function screens in 28 BC cell lines (Supplementary Table S23). 
Our results showed 310 dependencies with at least one score ≤ −1 in 34 (16%) essential genes. Figure 7b shows 
the distribution of dependency scores of DEMETER2 and CERES per molecular subtype. The genome-scale 
RNAi loss-of-function screens detected 165 (29%) dependencies in 19 Her2-enriched cell lines (ratio = 8.7), 110 
(20%) in 13 luminal A cell lines (8.5), 57 (10%) in 7 luminal B cell lines (8.1), and 231 (41%) in 34 basal-like cell 
lines (6.8), whereas the genome-scale CRISPR-Cas9 loss-of-function screens detected 85 (27%) dependencies in 
7 luminal A cell lines (ratio = 12.1), 176 (15%) in 16 basal-like cell lines (11), and 49 (16%) in 5 Her2-enriched 
cell lines (9.8). Figure 7c shows violin plots of dependencies per molecular subtype. DEMETER2 has detected a 
greatest number of substantial dependencies in basal-like, followed by Her2-enriched, luminal A and luminal B, 
whereas CERES has detected a greatest number of substantial dependencies in basal-like, followed by luminal A 
and Her2-enriched. Figure 7d shows a Venn diagram of 22 strongly selective genes, 26 common essential genes, 
and 5 strongly selective and common essential genes in breast and other cancer cell lines.
Patient-derived xenografts. The second analysis of the fourth OncoOmics approach consisted in identi-
fying proteins with significant expression in PDXs. According to Woo et al., PDXs are in vivo models of human 
cancer that are useful for translational cancer research and therapy selection for individual patient. We ana-
lyzed the 66 strongly selective and common essential genes of BC cell lines using the Jackson Laboratory PDX 
resource59. Figure 7e shows 7 proteins with significant high expression (Z-score ≥ 2) and 33 proteins with sig-
nificant low expression (Z-scores ≤ −2) with its respective mice model ID. As result, the fourth OncoOmics 
approach revealed 38 proteins with significant expression in both BC cell lines and patient-derived xenografts 
(Supplementary Tables S22 and S23).
OncoOmics approaches to reveal essential genes in BC. After analyses of the four OncoOmics 
approaches (genomic alterations, String PPi network, protein expression and BC dependencies/patient-derived 
xenografts), we used a Venn diagram to integrate essential genes, termed OncoOmics BC essential genes. 
Consequently, we could observe 140 essential genes in at least one OncoOmics approach; of them, 92 were 
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essential in one OncoOmics approach, 30 were essential in two OncoOmics approaches, 13 were essential 
in three OncoOmics approaches, and 5 were essential in all OncoOmics approaches as shown in Fig. 8a and 
Supplementary Table S24.
The 140 OncoOmics BC essential genes were conformed by oncogenes (21%), tumor suppressor genes (24%) 
and driver genes in other cancer types (59%)60 (Fig. 8b). Additionally, some of these OncoOmics BC essential 
genes were involved in cancer immunotherapy61, kinome signaling62, cell cycle63, DNA repair64 and RNA-binding 
as shown in Fig. 8c and Supplementary Table S2565.
Figure 8d shows a circos plot detailing the correlation between 48 (34%) OncoOmics BC essential genes and 
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Figure 5. Protein-protein interactome network. (a) Network composed of BC driver genes and genes of our 
study (PCA gene set, consensus strategy gene set and PharmGKB gene set. (b) Significant correlation (P < 0.05) 
of degree centrality and consensus score between the OncoPPi BC network and our String PPi network.
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immune response to cancer was promoted by CTNNB1, EGFR and RAC1; cell replicative immortality was pro-
moted by CTNNB1, KRAS and NOTCH1; tumor promoting inflammation was promoted by KRAS; metastasis 
was promoted by ABL1, CTNNB1, EGFR, KRAS, RAC1 and RB1; angiogenesis was promoted by ABL1, CTNNB1, 
EGFR, KRAS, NOTCH1 and RAC1; genome instability was promoted by ABL1 and RB1; escaping programmed 
cell death was promoted by AKT1, CTNNB1, EGFR, NOTCH1; change of cellular energetics was promoted by 
ABL1, AKT1, CTNNB1, EGFR, KRAS, NOTCH1, PTEN, RB1 and TP53; finally, proliferative signaling was pro-
moted by ABL1, AKT1, CTNNB1, EGFR, KRAS, NOTCH and RAC1 (Supplementary Table S26).
Enrichment map of the OncoOmics BC essential genes. Figure 8e shows the enrichment map of the 
140 OncoOmics BC essential genes. g:Profiler searches for a collection of genes representing GO terms, path-
ways and disease phenotypes66. The most significant GO: biological processes with a FDR < 0.001 was positive 
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Figure 6. Protein expression analyses. (a) Proteins (n = 43) with alterations in the expression levels. Low 
expression proteins with Z-score ≤ −2 and high expression proteins with Z-score ≥ 2 according to TCGA. (b) 
Comparison of protein expression levels (n = 202) by immunohistochemistry between BC tissue and normal 
tissue according to The Human Protein Atlas.
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regulation of macromolecule metabolic process (Supplementary Table S27); the most significant GO: molecular 
function was phosphatidylinositol 3-kinase activity (Supplementary Table S28); the most significant Reactome 
pathway was generic transcriptor pathway (Supplementary Table S29)67; additionally, the most relevant disease, 
according the Human Phenotype Ontology, was breast carcinoma (Supplementary Table S30)68. Subsequently, 
g:Profiler annotations were analyzed with the EnrichmentMap software and visualized using Cytoscape, in order 
to generate network interactions of the most relevant GO: biological processes (Supplementary Fig. S2) and 
Reactome pathways (Fig. 9) related to immune system, tyrosine kinase, cell cycle and DNA repair pathways54,66.
Clinical trials. Figure 10 and Supplementary Table S31 details the current status of clinical trials regarding 
OncoOmics BC essential proteins, according to the Open Targets Platform69. There are 98 drugs that are being 
analyzed in 2,904 clinical trials in 28 of 140 OncoOmics BC essential proteins (Fig. 10a). The top 10 drugs with 
the highest number of clinical trials in process or completed were paclitaxel (370), trastuzumab (315), docetaxel 
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Figure 7. BC dependency maps in cell lines and patient-derived xenografts. (a) Dependency score of gene 
sets using RNAi DIMETER2 and CRISPR-Cas9 CERES algorithms in BC cell lines. (b) Dependency score of 
BC gene sets per molecular subtypes. (c) Violin plots of dependencies per molecular subtypes. All substantial 
dependencies < −1 are in black. (d) Venn diagram of strongly selective and common essential genes in all 
cancer cell lines. (e) Significant protein expression from patient-derived xenografts.
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(262), doxorubicin (204), gemcitabine (196), lapatinib (152), tamoxifen (131), fulvestrant (129), bevacizumab 
(120) and neratinib (110). Regarding drugs, 94% were antagonists, 79% were small molecules, and 35% were 
protein kinases as shown in Fig. 10b–d, respectively. Additionally, drugs with the highest number of clinical trials 
in phases 3 and 4 were paclitaxel (111), docetaxel (105), trastuzumab (80), tamoxifen (69) and doxorubicin (60) 
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OncoOmics BC essential genes
n = 140
GRB2
Figure 8. OncoOmics BC essential genes. (a) Venn diagram of the most essential genes per genomics approach 
(genomic alterations, String PPi network, protein expression, and BC dependencies/patient-derived xenografts). 
(b) Percentage of oncogenes, tumor suppressor genes and driver genes in other cancer types. (c) Venn diagram 
of the most essential genes related to cancer immunotherapy, kinome signaling, cell cycle, DNA repair and 
RNA-binding proteins. (d) Circos plot of genes with hallmarks of cancer. (e) Most significant g:Profiler features 
of the OncoOmics BC essential genes according to GO: biological processes, Reactome pathways, WikiPathways 
and the human phenotype ontology.
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Precision medicine. Precision oncology focuses on matching the most effective and safe treatment based 
on the ‘omics’ profile of each individual or population70,71. However, the identification of driver mutational events 
remains the biggest challenge72. There are some consortiums and studies that have robustly identified variants 
associated with BC. Tamborero et al. detailed a compendium of 62 somatic and 398 germline validated oncogenic 
mutations in 14 OncoOmics BC essential genes (Supplementary Table S32)38. Huang et al. identified 87 patho-
genic germline variants in 22 OncoOmics BC essential genes73 (Supplementary Table S33). Long et al.74,75, Cai et 
al.76, Michailidou et al.77, and the Breast Cancer Association Consortium performed genome-wide association 
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Figure 9. Pathway enrichment analysis of the OncoOmics BC essential genes using g:Profiler and 
EnrichmentMap. Most significant Reactome pathways related to immune system, kinome signaling, cell cycle, 
DNA repair and genetic transcription.
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studies identifying 172 germline variations related to BC development (Supplementary Table S34). The Precision 
Medicine Knowledgebase (PreMedKB) detailed a compendium of 2791 germline variants in 7 OncoOmics 
BC essential genes (Supplementary Table S35)71. PharmGKB enriched clinical guidelines with 59 well-known 
clinical annotations related to 29 OncoOmics BC essential genes (Supplementary Table S36)42,78,79. Finally, the 
Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium identified 19 non-coding somatic mutations and 
17 coding somatic mutations in BC (Supplementary Table S37)6.
Regarding the Ensembl Variant Effect Predictor80, 1,102 of 3,565 variants were processed, being 24% intron 
variants, 16% missense variants, 15% downstream gene variants, 10% stop gained, 7% upstream gene variants, 7% 
NMD transcript variants, 4% splice region variants, 4% 3′ untranstaled region variants, and 2% splice acceptor 
variants (Supplementary Table S38).
Consequently, based on the aforementioned somatic and germline oncogenic variants, the Cancer Genome 
Interpreter and PreMedKB platforms provided a comprehensive in silico list of biological therapy drugs aimed to 



























































































Figure 10. Current status of clinical trials in the OncoOmics BC essential proteins. (a) Clinical trials   per 
phase. (b) Clinical trials per activity. (c) Clinical trials per type. (d) Clinical trials per target class. (e) Correlation 
of drugs with proteins in advanced stages of clinical trials (3 and 4) using a Sankey plot.
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Discussion
In this study we reveal essential genes in breast cancer through an OncoOmics strategy that analyzes genomic 
alterations, PPi networking, protein expression, dependency maps and patient-derived xenografts in three gene 
sets. The first gene set was taken from our previous study where we developed a Consensus Strategy that was 
proved to be highly efficient in the recognition of BC pathogenic genes29,41. The second gene set was taken from 
several studies of PCA, which provides a panoramic view of the oncogenic processes that contributes to BC 
pathogenesis3,13,31–37. The third gene set was taken from the CGI and PharmGKB. On the one hand, the CGI flags 
genomic biomarkers of drug response with different levels of clinical relevance38. On the other hand, PharmGKB 
collects clinical annotations applied in BC patients and taken from the NCCN, ESMO, CPNDS, DPWG and CPIC 
















































































































































Druggability of 50 OncoOmics BC essential proteins
Figure 11. Precision medicine. Interaction between drugs and 50 OncoOmics BC essential proteins.
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The first OncoOmics approach consisted in the analysis of genomic alterations using the PCA data47,48. The 
frequency mean of genomic alterations in the CS (1.2) and PCA (1.3) gene sets were significantly higher than both 
the non-cancer genes (0.4) and the well-known BC driver genes (0.8), with a significant Bonferroni correction of 
P < 0.001. This means that the analyzed set of genes might be strongly associated with BC (Fig. 1a).
The most common genomic alterations in a cohort of 994 individuals were mRNA up-regulation, CNV 
amplification and missense mutations. Regarding molecular subtypes, basal-like showed the highest amount of 
genomic alterations. PIK3CA was the most altered gene in luminal A, CCND1 in luminal B, TP53 in basal-like 
and normal-like, and ERBB2 in Her2-enriched (Fig. 2a). A multiple comparison through Bonferroni correction 
found significant differences (P < 0.05) of CNV amplifications, CNV deep deletions, mRNA up-regulations, and 
mRNA down-regulations among molecular subtypes (Figs. 2c–f). Regarding tumor stages, T2 showed the highest 
amount of genomic alterations. PIK3CA was the most altered gene in T1, TP53 in T2 and T3, and ERBB2 in T4 
(Fig. 2g). Bonferroni correction found significant differences (P < 0.05) in punctual mutations, CNV amplifica-
tions, CNV deep deletions, mRNA up-regulations, and mRNA down-regulations among tumor stages (Fig. 2h–l). 
Lastly, the first OncoOmics approach revealed that 73 essential genes presented frequencies of alteration higher 
than the average (Fig. 3a)3,13,31–37.
Subsequently, the enrichment analysis of signaling pathways was carried on taking into account all genomic 
alterations in the 230 genes using David Bioinformatics Resource and KEGG49,52. Pathways with the highest 
amount of genomic alterations per molecular subtype were Jak-STAT in luminal A, Wnt in luminal B, p53 in 
basal-like, ERBB in Her2-enriched and Hippo in normal-like. Bonferroni correction showed significant dif-
ferences (P < 0.05) among several subtypes as shown in Fig. 4b. On the other hand, pathways with the high-
est amount of genomic alterations per tumor stage were Wnt in T1, T2 and T3, and thyroid hormone in T4. 
Bonferroni correction showed significant differences (P < 0.05) comparing T1 with T2 and T4 as shown in 
Fig. 4d.
Regarding previously mentioned signaling pathways, Jak-STAT is involved in inflammatory response, stem 
cell maintenance, and hematopoiesis81. The Wnt signaling pathway actively functions in embryonic development 
and helps in homeostasis in mature tissues by regulating cell survival, migration, proliferation, and polarity82. The 
p53 signaling pathway plays an essential role into inhibition of growth, programmed cell death, cell migration 
and angiogenesis83. The ERBB pathway mediates signal transduction events that control cell survival, migration 
and proliferation in BC84. The Hippo pathway plays important roles in tumor suppression and immune response. 
However, alterations in this pathway are involved in the BC tumorigenesis and metastasis85. Lastly, the thyroid 
hormone pathway plays an important role as regulator of growth and metabolism. Nevertheless, dysfunction of 
the T3 hormone promotes cancer progression in mammary epithelial cells86.
The second OncoOmics approach was focused on proteins with the highest degree centrality and consensus 
score in the String PPi network. In accordance with Li et al. and Ivanov et al.56,87, PPi with therapeutic significance 
can be revealed by the integration of cancer proteins into networks. PPi regulate essential oncogenic signals to 
cell proliferation and survival, and thus, represents potential targets for drug development and drug discovery. 
Regarding our networking analysis, the final interaction network consisted in 258 nodes with a degree centrality 
average of 48.8 and a consensus score average of 0.80329; the sub-network integrated by 198 of 230 nodes had 52.7 
of degree centrality and 0.812 of consensus scoring; finally, the sub-network integrated by 65 of 73 proteins with 
the highest amount of genomic alterations had 61.7 of degree centrality and 0.833 of consensus score. Hence, 
a sub-network of nodes with the highest amount of genomic alterations presented a highest degree centrality 
and consensus score, suggesting that there is strong correlation between these proteins and BC. Additionally, 
the oncogenomics validation showed a substantial correlation between our String PPi network (Fig. 5a) and 
the OncoPPi BC network (Fig. 5b), identifying 16 nodes strongly associated with BC29. The second OncoOmics 
approach revealed 40 essential proteins with the highest degree centrality and consensus scoring.
The third OncoOmics approach was focused on proteins with significant high and low expression in BC 
proteome. More than 500 proteins have been identified as strongly involved in oncogenesis. Loss of expression, 
overexpression or expression of dysfunctional proteins contribute to uncontrolled tumor growth, causing chro-
mosomal rearrangements, gene amplification and ungoverned methylation88. Regarding our 230 proteins, 43 
showed significant high (Z-scores ≥ 2) and low (Z-scores ≤ −2) expression according to TCGA89 (Fig. 6a); and 
16 proteins showed opposite expression between healthy and affected tissues after microarray-based immunohis-
tochemistry according to the Human Protein Altas (Fig. 6b)57,58. The compendium of 60 proteins with significant 
high and low expressions made up the third OncoOmics approach.
The fourth OncoOmics approach was related to the BC dependency map in cell lines and patient-derived 
xenografts. According to Tsherniak et al., mutations that trigger the growth of cancer cells also confer spe-
cific vulnerabilities that normal cells lack, and these dependencies are compelling therapeutic targets19. The 
cancer dependency map identifies essential genes in proliferation and survival of well-annotated cell lines 
through systematic loss-of-function screens19–22. On the one hand, DETEMER2 analyzed the genome-scale 
RNAi loss-of-function screens, and on the other hand, CERES analyzed the genome-scale CRISPR-Cas9 
loss-of-function screens as shown in Fig. 7a. In addition to the loss-of-function screens in a large number of 
well-annotated BC cell lines, the patient-derived xenografts are in vivo models of human tumors engrafted in 
a mouse host and emerging as a powerful tool for understanding tumor hallmarks and predicting drug effi-
cacy90. Consequently, we validated the genomic expression of the strongly selective and common essential genes 
(dependencies in BC cell lines) in breast tumors from PDXs provided by the Jackson Laboratory59. The fourth 
OncoOmics approach was made up of 38 essential proteins in BC (Fig. 7e).
Subsequently, the compendium of essential genes per approach reveals the 140 OncoOmics BC essential genes 
(Fig. 8a). RAC1, AKT1, CCND1, PIK3CA and ERBB2 were essential genes in all the OncoOmics approaches. 
CDH1, MAPK14, TP53, MAPK1, SRC and RAC3 showed genomic alterations, highest degree centrality and con-
sensus scores in the String PPi network, and significant protein expression. GRB2 showed genomic alterations, 
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highest degree centrality and consensus scores in the String PPi network, and substantial relevance in BC cell 
lines and PDXs. MED1 and GATA3 showed genomic alterations, significant protein expression, and considerable 
relevance in BC cell lines and PDXs. Lastly, BCL2, CTNNB1, EGFR and CDK2 showed significant protein expres-
sion, highest degree centrality and consensus scores in the String PPi network, and substantial relevance in BC 
cell lines and PDXs.
Relevant studies worldwide have identified OncoOmics BC essential genes. For instance, genome-wide asso-
ciation studies performed by the Breast Cancer Association Consortium showed that BRCA2, CHEK2, ESR1, 
FGFR2, MDM4 and PIK3R3 carry germline variants associated with BC development74–77. According to Bailey 
et al., identifying molecular cancer drivers is critical for precision oncology32. Their final consensus list was con-
formed by 29 BC driver genes, of them, 22 were OncoOmics BC essential genes (AKT1, ARID1A, BRCA1, CASP8, 
CDH1, CDKN1B, CTCF, ERBB2, FOXA1, GATA3, KMT2C, KRAS, MAP2K4, MAP3K1, NCOR1, NF1, PIK3CA, 
PIK3R1, PTEN, RB1, SF3B1 and TP53). According to Gonzalez-Perez et al., the IntOGen-mutation platform 
summarizes somatic mutations involved in tumorigenesis91. Their final consensus list was conformed by 99 muta-
tional BC driver genes, of them, 34 were identified by the OncoOmics strategy (TP53, PIK3CA, KMT2C, GATA3, 
CDH1, MAP3K1, ESR1, PTEN, AKT1, NCOR1, ARID1A, MAP2K4, FOXA1, NF1, ERBB2, RB1, SF3B1, ERBB3, 
CTCF, PIK3R1, ATM, FGFR2, BRCA1, CASP8, CREBBP, BRCA2, CDKN2A, KRAS, CDKN1B, NOTCH2, MAX, 
MDM4, EGFR and JAK2). Finally, the PCAWG Consortium of the International Cancer Genome Consortium 
(ICGC) and The Cancer Genome Atlas reported an integrative analysis of 2,658 whole-cancer genomes across 
38 tumor types92. Regarding breast cancer, PCAWG identified 27 mutational BC driver genes, of them, 15 were 
OncoOmics BC essential genes (TP53, PIK3CA, MAP3K1, KMT2C, NOTCH2, SF3B1, PTEN, ARID1A, MAP2K4, 
AKT1, CTCF, FOXA1, RB1, CDKN2A and ATM).
According to Reimand et al., g:Profiler lets us know the enrichment map of the 140 OncoOmics BC essen-
tial genes66. The most significant GO: biological process was the positive regulation of macromolecule meta-
bolic process, the GO: molecular function was phosphatidylinositol 3-kinase activity, the Reactome pathway was 
generic transcriptor pathway, and the most significant Human Phenotype Ontology term was breast carcinoma68. 
Subsequently, the most relevant network interactions of the GO: biological process and the Reactome pathways 
were related to immune system, tyrosine kinase, cell cycle and DNA repair terms (Figs. 9 and S2)54,66.
There is currently great enthusiasm about immunotherapeutic strategies to treat BC93. The first approval of 
an immune checkpoint blockade agent for treatment of BC came in March 2019 when the anti-PD-L1 antibody 
atezolizumab was approved to be used with nab-paclitaxel in triple-negative BC patients94,95. 16 OncoOmics BC 
essential genes were associated with immunotherapy61,96 as shown in Fig. 8C. Kinases have been recognized as 
therapeutic targets due to their druggability and play a critical role in cell migration, differentiation, growth and 
survival97. 15 OncoOmics BC essential genes were kinomes62. Cell cycle comprises a series of events that drive 
cell division and DNA replication98. 12 OncoOmics BC essential genes were involved in cell cycle63. DNA repair 
signaling pathways work in concert to correct DNA lesions and maintain genome stability. Nevertheless, a defec-
tive DNA repair machinery causes BC development and progression99. 17 OncoOmics BC essential genes were 
involved in DNA repair64. RBPs are key players in post-transcriptional events and are emerging as critical mod-
ulators in BC100–102. Bioinformatics profiling of tumors have revealed the landscape of alterations in RBPs across 
cancer types103–106. Lastly, 10 OncoOmics BC essential genes were RBPs65.
Regarding clinical trials reported on the OncoOmics BC essential proteins, the Open Targets Platform is an 
available resource for the integration of genomics and chemical data to aid systematic drug target identification 
and prioritization69. There are 98 drugs that are being analyzed in 2,904 clinical trials in 28 of 140 OncoOmics 
BC essential proteins. Additionally, there are 30 drugs involved in 736 clinical trials in phases 3 and 4. The top 
five drugs with the highest number of clinical trials in process or completed are paclitaxel (111), docetaxel (105), 
trastuzumab (80), tamoxifen (69), and doxorubicin (60)69 (Fig. 10e).
Tumor-related genomic alterations predict tumor prognosis, drug response, and toxicity107. Precision medi-
cine provides patients with the most appropriate diagnostics and targeted therapies based on the ‘omics’ profile 
and other predictive and prognostic tests108. Therefore, precision medicine aims to deliver the right medicine to 
the right patient at the right dose at the right time, minimizing adverse effects and maximizing drug efficacy109,110. 
Figure 11 shows comprehensive interactions between directed biological drugs and 50 OncoOmics BC essential 
proteins aimed to improve precision medicine in breast cancer.
In conclusion, since BC is a complex and heterogeneous disease, the study of different OncoOmics approaches 
is an effective way to reveal essential genes to better understand the molecular landscape of processes behind 
oncogenesis, and to develop better therapeutic treatments focused on pharmacogenomics and precision 
medicine.
Methods
OncoPrint of genomic alterations according to the Pan-Cancer Atlas. PCA has reported the clin-
ical data of 1084 individuals with BC and it can be visualized in the Genomic Data Commons of the National 
Cancer Institute (https://gdc.cancer.gov/) and in the cBioPortal (http://www.cbioportal.org/)47,48. The clinical 
annotations were age, pTNM classification, tumor type, tumor stage and race/ethnicity.
Additionally, PCA has reported genomic alterations (mRNA up-regulation, mRNA down-regulation, CNV 
amplification, CVN deep deletion, putative driver mutations and fusion gene) of 994 individuals. Putative muta-
tions were analyzed through exome sequencing, CNVs through the Genomic Identification of Significant Targets 
in Cancer (GISTIC 2.0)111,112, and mRNA expression through RNA Seq V2. We analyzed five gene sets in order to 
compare the frequency mean of genomic alterations among them. The first gene set (n = 177) was integrated by 
the non-cancer genes113. We calculated the OncoScore of non-cancer genes, taking out all genes from our study. 
The second gene set (n = 119) was the BC driver genes, according to The Network of Cancer Genes60. The third 
gene set (n = 84) was taken from our previous study where we developed a Consensus Strategy of prioritized 
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genes related to BC pathogenesis29. The fourth gene set (n = 85) was made up of genes associated with BC devel-
opment, according to several PCA studies31,32,114. Finally, the fifth gene set (n = 91) consisted of BC biomarkers 
and druggable enzymes taken from PharmGKB and the CGI (Supplementary Table S2)38,39,42.
The OncoOmics approaches were performed in 230 genes conformed by the CS, PCA and PharmGKB/
CGI gene sets. We calculated the percentage and ratio of genomic alterations per intrinsic molecular subtype 
and tumor stage, and then we established a ranking of genes with the highest amount of genomic alterations 
(OncoPrint). The OncoPrint conformed the first OncoOmics approach.
Pathway enrichment analysis. The enrichment analysis of signaling pathways was performed using 
David Bioinformatics Resource to obtain integrated information from KEGG49–52. It was carried on in the 230 
genes, taking into account terms with a significant FDR < 0.01. After that, genomic alterations that comprise 
each signaling pathway were analyzed, taking into account the molecular subtype and tumor stage of individuals 
from PCA. Circos plots and violin plots were designed to visualize all data. Lastly, in order to compare the ratio 
of genomic alterations among subtypes and tumor stages, normalization was carried out dividing the number of 
genomic alterations by the number of individuals per subtype and tumor stage. Regarding molecular subtypes, 
499 individuals were luminal A, 197 were luminal B, 171 were basal-like, 78 were Her2-enriched and 36 were 
normal-like, and regarding tumor stage, 255 were T1, 586 were T2, 113 were T3, and 103 were T4.
Protein-protein interactome network. The PPi network with a highest confidence cutoff of 0.9 and zero 
node addition was created using the String Database, which takes into account predicted and known interac-
tions53. The confidence scoring is the approximate probability that a predicted link exists between two enzymes 
in the same metabolic map, whereas the degree centrality of a node means the number of edges the node has to 
other nodes in a network. The centrality indexes calculation and network visualization were analyzed through 
the Cytoscape software54. Proteins with the highest degree centrality, consensus score and sub-networks were 
differentiated by colors in the PPi network. On the other hand, OncoPPi (http://oncoppi.emory.edu/) reports 
the development of a cancer-focused PPi network, identifying more than 260 high-confidence cancer-associated 
PPi55,56. In addition, the OncoPPi BC network consisted of 16 proteins and 18 PPi experimentally analyzed in BC 
cell lines55,56. The correlation of the degree centrality by means of Spearman P-value test between our String PPi 
network and the OncoPPi BC network allowed for the validation of all the high-confidence BC-focused PPi ana-
lyzed in cell lines29. Lastly, proteins with the highest degree centrality and consensus scoring made up the second 
OncoOmics approach.
Protein expression analysis. TCGA has reported the protein expression data of 994 individuals with BC 
through RPPA and mass spectrometry by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and it 
can be visualized in the cBioPortal47,48. We analyzed the protein expression of 230 protein where Z-scores ≥ 2 
mean a significant high protein expression and Z-scores ≤ −2 mean a significant low protein expression.
On the other hand, the Human Protein Atlas (https://www.proteinatlas.org/) explains the diverse molecular 
signatures of proteomes in human tissues based on an integrated ‘omics’ approach that involves quantitative 
transcriptomics and tissue microarray-based immunohistochemistry58,88,115. We compared the protein expres-
sion levels (high, medium, low and non-detected) of our 230 proteins between normal and BC tissues. Finally, all 
genes with the altered protein expression made up the third OncoOmics approach.
Breast cancer dependency map. The DepMap project (https://depmap.org/portal/) is collaboration 
between the Broad Institute and the Welcome Sanger Institute. Multiple genetic or epigenetic changes provide 
cancer cells with specific vulnerabilities that normal cells lack. Even though the landscape of genomic alterations 
has been extensively studied to date, we have limited understanding of the biological impact of these altera-
tions in the development of specific tumor vulnerabilities, which triggers a limited use of precision medicine 
in the clinical practice worldwide. Therefore, the main goal of DepMap is to create a comprehensive preclinical 
reference map connecting tumor features with tumor dependencies to accelerate the development of precision 
treatments19–22.
In order to identify essential genes for BC cell proliferation and survival, DepMap performed systematic 
loss-of-function screens in a large number of well-annotated BC cell lines representing the tumor heteroge-
neity and their molecular subtypes. The DEMETER2 algorithm was applied to analyze genome-scale RNAi 
loss-of-function screens in 73 BC cell lines and 711 cancer cell lines, whereas the CERES algorithm was applied to 
analyze genome-scale CRISPR-Cas9 loss-of-function screens in 28 BC cell lines and 558 cancer cell lines20,22. In 
addition to existing cell lines, the Cancer Cell Line Encyclopedia (CCLE) project will greatly expand the collec-
tion of characterized cell lines to improve precision treatments116.
Regarding dependency scores, a lower score means that a gene is more likely to be dependent in a specific 
cancer cell line. A score of 0 means that a gene is not essential, whereas a score of −1 corresponds to the median of 
all common essential genes. A strongly selective gene means that its dependency is at least 100 times more likely 
to have been sampled from a skewed distribution than a normal distribution. A common essential gene is when 
in a pan-cancer screen its gene ranks in the top most depleting genes in at least 90% of cell lines19. All genes or 
proteins with a dependency score ≤ −1 were subsequently analyzed with patient-derived xenografts.
Patient-derived xenografts. The Jackson Laboratory PDX resource (http://tumor.informatics.jax.org/
mtbwi/pdxSearch.do) comprises 455 PDX models originating from 34 different primary sites59. Even though, we 
analyzed expression levels of strongly selective and common essential proteins in breast cancer obtained from the 
analysis of BC dependency map in cell lines. Significant high protein expression has a Z-score ≥ 2 and significant 
low protein expression has a Z-scores ≤ −2.
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Enrichment map of the OncoOmics BC essential genes. The pathway enrichment analysis gives sci-
entists curated interpretation of gene lists generated from genome-scale experiments66. The OncoOmics essential 
genes in BC were analyzed by using g:Profiler (https://biit.cs.ut.ee/gprofiler/) in order to obtain significant anno-
tations (FDR < 0.001) related to GO terms, pathways, networks and disease phenotypes. Subsequently, g:Pro-
filer annotations were analyzed with the EnrichmentMap software in order to generate network interactions of 
the most relevant GO: biological processes and Reactome pathways, and these networks were visualized using 
Cytoscape54,66.
Clinical trials. The Open Targets Platform (https://www.targetvalidation.org) is comprehensive and robust 
data integration for access to and visualization of drugs involved in clinical trials associated with BC proteins, 
detailing its phase, status, type and target class69. In addition, we created a Sankey plot to better understand which 
drugs are involved in the most advanced phases (3 and 4) of clinical trials.
Precision medicine. Precision oncology focuses on matching the most effective treatment based on the 
‘omics’ profile of each individual or population70,71. The CGI (https://www.cancergenomeinterpreter.org/home) 
flags genomic biomarkers of drug response with different levels of clinical relevance38. Huang et al. and the 
Pan-Cancer Atlas project conducted the largest investigation of pathogenic germline variants in cancer73. Long 
et al.74,75, Cai et al.76, and Michailidou et al.77, performed genome-wide association studies identifying germline 
variations related to BC development. PreMedKB (http://www.fudan-pgx.org/premedkb/index.html#/home) is 
a bioinformatics tool that facilitates the interpretation of the clinical meaning of a patient's genetic variants71. 
PharmGKB (https://www.pharmgkb.org/) collected complete guidelines for application of pharmacogenomics in 
clinical practice, according to several consortiums worldwide43–46. Finally, PCAWG Consortium (https://dcc.icgc.
org/) revealed an integrative analysis of genomic alterations in coding and non-coding regions6,92.
Based on the aforementioned somatic and germline oncogenic variants we performed two analyses. On the 
one hand, we analyzed the consequence type of variants with the Ensembl Variant Effector Predictor (https://
www.ensembl.org/Multi/Tools/VEP?db=core), which is a powerful toolset for the annotation of genomic vari-
ants in coding and non-coding regions80. On the other hand, we analyzed oncogenic variants through the Cancer 
Genome Interpreter and PreMedKB platforms to provide a comprehensive in silico list of biological therapy 
drugs38,71.
Statistical analyses. We performed a multiple comparison using the Bonferroni correction test (significant 
level of P < 0.05 and a 95% confidence interval) to analyze: 1) significant differences of genomic alteration fre-
quencies among non-cancer genes, BC driver genes, Consensus Strategy, Pan-Cancer Atlas and PharmGKB/CGI 
genes; 2) significant differences of genomic alteration frequencies among intrinsic molecular subtypes and tumor 
stages; 3) significant differences of genomic alteration frequencies of signaling pathways among molecular sub-
types and tumor stages. A significant correlation of the degree centrality between the String PPi network and the 
OncoPPi BC network was performed using the Spearman p-value test with a P < 0.05. The significant high and 
low protein expression in humn tissues and patient-derived xenografts was considered using the Z-score. Z-score 
≥ 2 means significant high protein expression and Z-scores ≤ −2 means significant low protein expression. 
Lastly, the enrichment map of OncoOmics BC essential genes was performed using g:Profiler that determines the 
most significant GO: biological processes, GO: molecular functions, Reactome pathways, WikiPathways, KEGG 
pathways and human phenotype ontology with a false discovery rate <0.001.
Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files).
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